Comparison of Two Artificial Liver Support Treatments for Acute-on-Chronic Liver Failure
A Multicenter, Prospective, Non-Inferiority Cohort Study of Plasma Exchange Combined With Double Plasma Molecular Adsorption System (PE+DPMAS) Versus Plasma Exchange Combined With Continuous Renal Replacement Therapy (PE+CRRT) in Patients With Acute-on-Chronic Liver Failure
This study compares two blood-filtering treatment approaches used in adults with acute-on-chronic liver failure, a sudden worsening of liver function in people with long-term liver disease.
Both approaches include plasma exchange, which removes and replaces the liquid part of the blood. One approach combines plasma exchange with a system that uses filters to remove certain substances from the blood. The other combines plasma exchange with continuous kidney support therapy, which helps remove waste and excess fluid.
The treating doctors and patients decide which treatment to use as part of routine care. The study does not assign treatment. The researchers will follow participants to find out how many are alive without a liver transplant 90 days after joining the study. They will also compare complications, blood test results, and safety outcomes. Participants may choose to join a separate part of the study that collects blood and stool samples.
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
This multicenter, prospective, observational cohort study uses a noninferiority design to compare two artificial liver support strategies in adults with acute-on-chronic liver failure: plasma exchange plus double plasma molecular adsorption system (PE plus DPMAS) and plasma exchange plus continuous renal replacement therapy (PE plus CRRT).
The planned enrollment is 400 participants across two hospitals, with a target of 200 participants in each cohort. Treatment decisions are made in routine clinical practice by the treating clinicians in consultation with patients. Participants are grouped according to the treatment they receive. The study protocol does not assign treatment, and there is no randomization.
The primary outcome is 90-day transplant-free survival, measured from enrollment. The first occurrence of death from any cause or liver transplantation is counted as an event. An independent committee blinded to treatment group adjudicates the primary outcome events. The analysis will use propensity score matching to address measured differences between the two cohorts.
An optional exploratory substudy plans to enroll 120 consenting participants. Research blood samples will be used for peripheral blood mononuclear cell single-cell RNA sequencing and plasma-based omics analyses. Stool samples will be used to characterize the gut microbiome. Participants may decline the substudy and still participate in the main cohort.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Shan Zhong
- Phone Number: +86 186 2304 1122
- Email: zhongshan@cqmu.edu.cn
Study Locations
-
-
Chongqing Municipality
-
Chongqing, Chongqing Municipality, China, 400010
- The Second Affiliated Hospital of Chongqing Medical University
-
Contact:
- Shan Zhong
- Phone Number: +86 186 2304 1122
- Email: zhongshan@cqmu.edu.cn
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310023
- Hangzhou Xixi Hospital
-
Contact:
- Rui Wu
- Phone Number: +86 13655813566
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
The study population consists of adults aged 18 to 80 years with acute-on-chronic liver failure who are scheduled to receive artificial liver support for the first time at one of two participating hospitals in China. Eligible patients who provide written informed consent are enrolled prospectively. The two cohorts are defined by the treatment received in routine clinical care: plasma exchange plus double plasma molecular adsorption system (PE plus DPMAS) or plasma exchange plus continuous renal replacement therapy (PE plus CRRT). The study protocol does not assign treatment.
Description
Inclusion Criteria:
- Age 18 to 80 years, inclusive, regardless of sex.
- Meets the protocol-defined AARC diagnostic criteria for acute-on-chronic liver failure, including all of the following:
- Underlying chronic liver disease, including compensated cirrhosis, decompensated cirrhosis, or noncirrhotic chronic liver disease.
- Acute hepatic decompensation within 4 weeks, presenting as jaundice and/or ascites and/or hepatic encephalopathy.
- Serum total bilirubin of at least 5 mg/dL (85 micromol/L), together with either prothrombin activity of 40% or less or an international normalized ratio (INR) of at least 1.5.
- Scheduled to receive artificial liver support for the first time, using either plasma exchange plus double plasma molecular adsorption system (PE plus DPMAS) or plasma exchange plus continuous renal replacement therapy (PE plus CRRT).
- Able to understand the study purpose and procedures, willing and able to comply with study requirements, and personally provides written informed consent.
- For the optional exploratory substudy only: agrees to provide blood and stool samples. Declining sample collection does not affect eligibility for the main cohort.
Exclusion Criteria:
- Primary liver cancer or another malignancy.
- Human immunodeficiency virus (HIV) infection.
- Expected death within 24 to 48 hours, as independently determined by two investigators. If the investigators disagree, this criterion alone does not exclude the patient.
- Pregnancy or breastfeeding.
- Another serious illness associated with a life expectancy of less than 6 months, as judged by the investigator.
- Current participation in another interventional clinical study.
- Temporary or persistent lack of capacity to provide informed consent.
- Any other circumstance that, in the investigator's judgment, makes the patient unsuitable for enrollment.
Study Plan
How is the study designed?
Design Details
- Observational Models: COHORT
- Time Perspectives: PROSPECTIVE
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
PE Plus DPMAS
Adults with acute-on-chronic liver failure who receive plasma exchange (PE) in combination with the double plasma molecular adsorption system (DPMAS) as part of routine clinical care. The study protocol does not assign treatment. |
|
PE Plus CRRT
Adults with acute-on-chronic liver failure who receive plasma exchange (PE) in combination with continuous renal replacement therapy (CRRT) as part of routine clinical care. The study protocol does not assign treatment. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
90-Day Transplant-Free Survival
Time Frame: From enrollment through Day 90
|
The percentage of participants who are alive and have not undergone liver transplantation at Day 90 after enrollment. Death from any cause or liver transplantation is counted as an event, whichever occurs first. |
From enrollment through Day 90
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
28-Day Transplant-Free Survival
Time Frame: From enrollment through Day 28
|
The percentage of participants who are alive and have not undergone liver transplantation at Day 28 after enrollment. Death from any cause or liver transplantation is counted as an event, whichever occurs first. |
From enrollment through Day 28
|
|
Occurrence of Liver Transplantation
Time Frame: From enrollment through Day 90
|
The percentage of participants who undergo liver transplantation during follow-up. The date of transplantation is recorded. |
From enrollment through Day 90
|
|
Change in Hepatic Encephalopathy Grade
Time Frame: Baseline and Day 28, Day 90, Week 24, and Week 48 after enrollment
|
Change in West Haven hepatic encephalopathy grade from baseline at each follow-up assessment, categorized as improvement, no change, or worsening. |
Baseline and Day 28, Day 90, Week 24, and Week 48 after enrollment
|
|
Reversal of Hepatorenal Syndrome
Time Frame: Baseline and Day 28, Day 90, Week 24, and Week 48 after enrollment
|
Percentage of participants with hepatorenal syndrome at baseline who meet the prespecified criteria for reversal at each follow-up assessment. Hepatorenal syndrome is diagnosed according to the International Club of Ascites criteria specified in the study protocol. |
Baseline and Day 28, Day 90, Week 24, and Week 48 after enrollment
|
|
Correction of Hyponatremia
Time Frame: Baseline and Day 28, Day 90, Week 24, and Week 48 after enrollment
|
Percentage of participants with hyponatremia at baseline who meet the prespecified correction criterion at each follow-up assessment, based on serum sodium measurements. |
Baseline and Day 28, Day 90, Week 24, and Week 48 after enrollment
|
|
Correction of Hyperkalemia
Time Frame: Baseline and Day 28, Day 90, Week 24, and Week 48 after enrollment
|
Percentage of participants with hyperkalemia at baseline who meet the prespecified correction criterion at each follow-up assessment, based on serum potassium measurements. |
Baseline and Day 28, Day 90, Week 24, and Week 48 after enrollment
|
|
Change From Baseline in SOFA Score
Time Frame: Baseline and Day 28, Day 90, Week 24, and Week 48 after enrollment
|
Change in the Sequential Organ Failure Assessment (SOFA) score from baseline at each follow-up assessment. The total score ranges from 0 to 24, with higher scores indicating more severe organ dysfunction. |
Baseline and Day 28, Day 90, Week 24, and Week 48 after enrollment
|
|
Relative Change in Total Bilirubin From Baseline During Serial Treatment and Follow-up
Time Frame: Baseline; within 48 hours before the start and after the end of each artificial liver support session; and Day 28, Day 90, Week 24, and Week 48 after enrollment
|
elative change in total bilirubin from baseline at each subsequent treatment-related and follow-up assessment, using the prespecified calculation method. Treatment-related measurements are obtained within 48 hours before the start and within 48 hours after the end of each artificial liver support session. Both increases and decreases are recorded. |
Baseline; within 48 hours before the start and after the end of each artificial liver support session; and Day 28, Day 90, Week 24, and Week 48 after enrollment
|
|
Change in Blood Ammonia From Baseline
Time Frame: Baseline; within 48 hours before the start and after the end of each artificial liver support session; and Day 28, Day 90, Week 24, and Week 48 after enrollment
|
Change in blood ammonia concentration from baseline at each postbaseline assessment, reported in micromoles per liter (μmol/L). Measurements are obtained within 48 hours before the start and within 48 hours after the end of each artificial liver support session, and at the scheduled follow-up assessments. |
Baseline; within 48 hours before the start and after the end of each artificial liver support session; and Day 28, Day 90, Week 24, and Week 48 after enrollment
|
|
Change in Serum Creatinine From Baseline
Time Frame: Baseline; within 48 hours before the start and after the end of each artificial liver support session; and Day 28, Day 90, Week 24, and Week 48 after enrollment
|
Change in serum creatinine concentration from baseline at each postbaseline assessment, reported in micromoles per liter (μmol/L). Measurements are obtained within 48 hours before the start and within 48 hours after the end of each artificial liver support session, and at the scheduled follow-up assessments. |
Baseline; within 48 hours before the start and after the end of each artificial liver support session; and Day 28, Day 90, Week 24, and Week 48 after enrollment
|
|
Change in INR From Baseline
Time Frame: Baseline; within 48 hours before the start and after the end of each artificial liver support session; and Day 28, Day 90, Week 24, and Week 48 after enrollment
|
Change in the international normalized ratio (INR) from baseline at each postbaseline assessment. Measurements are obtained within 48 hours before the start and within 48 hours after the end of each artificial liver support session, and at the scheduled follow-up assessments. |
Baseline; within 48 hours before the start and after the end of each artificial liver support session; and Day 28, Day 90, Week 24, and Week 48 after enrollment
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 20261030
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
There is no plan to share individual participant data with researchers outside the study team. Aggregate results may be reported in publications.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.